Shares of RTIX Up 19.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Dec 19, 11:02AM CST
SmarTrend identified an Uptrend for RTI Biologics (NASDAQ:RTIX) on October 30th, 2014 at $4.53. In approximately 2 months, RTI Biologics has returned 19.34% as of today's recent price of $5.40.
RTIX: 5.20 (unch)
Global Regenerative Medicine Market: 20.16% CAGR to 2019 Forecasts a New Research Report at ReportsnReports.com
PRWeb - Wed Dec 17, 10:30PM CST
The rise in prevalence of degenerative diseases is one of the main factors which is driving the growth of the global regenerative medicine market. Regenerative medicine is involved in the process of replacing or regenerating human tissues, cells and/or organs for normal functioning of the body. Small molecules and biologics, gene therapy, and cell therapy are the three main technologies which are used in regenerative medicine. The global market is expected to grow at a compound annual growth rate of 20.16% during the period from 2014 to 2019. Increase in demand for regenerative products and an increase in research and development are also fueling the growth in the global regenerative medicine market.
RTIX: 5.20 (unch), MDT: 74.08 (+0.31), PSTI: 2.46 (unch), OSIR: 14.87 (+0.13), OPXA: 0.80 (+0.01), FCSC: 2.38 (+0.04), BAX: 74.45 (-0.04), CYTX: 0.48 (-0.01)
United States Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry Analytics 2014-2021 - Market to reach $39.5 billion by 2021
M2 - Mon Dec 15, 8:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/s847lc/vaccines_skin) has announced the addition of Plunkett Research Ltd's new report "Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.) to reach $39.5 billion by 2021 Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked - Anika Therapeutics Inc - CSL Behring LLC - Emergent BioSolutions Inc - Halozyme Therapeutics Inc - LifeCell Corporation - Lifecore Biomedical Inc - MiMedx Group Inc - Organogenesis Inc - RTI Biologics Inc - Zoetis Inc For more information visit http://www.researchandmarkets.com/research/s8...cines_skin Source: Plunkett Research Ltd
ZTS: 43.84 (+0.87), RTIX: 5.20 (unch), HALO: 9.34 (+0.31), EBS: 27.64 (+1.28), ANIK: 38.26 (+0.73), MDXG: 11.17 (+0.17)
RTI Surgical Announces Retirement of Thomas F. Rose
Business Wire - Mon Dec 15, 7:30AM CST
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, announced today that Thomas F. Rose has informed the company of his intention to retire from his position as executive vice president of administration effective Dec. 31, 2014. Rose will continue to serve as corporate secretary for RTI's board of directors.
RTIX: 5.20 (unch)
RTI Surgical(TM) Hosts Winter Biologics Spine Symposium
Business Wire - Fri Dec 12, 3:30PM CST
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, is hosting a surgeon education symposium focused on the use of biologic implants in spine surgery tomorrow in New York.
RTIX: 5.20 (unch)
RTI Biologics Shares Up 17.3% Since SmarTrend's Buy Recommendation (RTIX)
Comtex SmarTrend(R) - Fri Dec 12, 9:38AM CST
SmarTrend identified an Uptrend for RTI Biologics (NASDAQ:RTIX) on October 30th, 2014 at $4.53. In approximately 1 month, RTI Biologics has returned 17.35% as of today's recent price of $5.31.
RTIX: 5.20 (unch)
RTI Biologics Has Returned 17.1% Since SmarTrend Recommendation (RTIX)
Comtex SmarTrend(R) - Fri Dec 05, 9:19AM CST
SmarTrend identified an Uptrend for RTI Biologics (NASDAQ:RTIX) on October 30th, 2014 at $4.53. In approximately 1 month, RTI Biologics has returned 17.13% as of today's recent price of $5.30.
RTIX: 5.20 (unch)
RTI Biologics Earnings In Retrospect: Up 6.3% in the Last 18 Days (RTIX)
Comtex SmarTrend(R) - Mon Nov 17, 4:02PM CST
When RTI Biologics (NASDAQ:RTIX) reported earnings two weeks ago on October 30th, 2014, analysts, on average, expected the company to report earnings of $0.02 on sales of $64.5 million. The company actually reported EPS of $0.03 on sales of $65.2 million, beating EPS estimates by $0.01 and beating revenue estimates by $0.6 million. Since the company's report, shares of RTI Biologics have risen from $4.76 to $5.06, representing a gain of 6.3% in the past 18 days.
RTIX: 5.20 (unch)
12.9% Return Seen to Date on SmarTrend RTI Biologics Call (RTIX)
Comtex SmarTrend(R) - Fri Nov 14, 9:57AM CST
SmarTrend identified an Uptrend for RTI Biologics (NASDAQ:RTIX) on October 30th, 2014 at $4.53. In approximately 2 weeks, RTI Biologics has returned 12.93% as of today's recent price of $5.11.
RTIX: 5.20 (unch)
RTI Surgical Announces Online Publication of Study Highlighting nanOss Advanced Bone Graft Substitute in The Journal of Spinal Disorders & Techniques
Business Wire - Wed Nov 12, 9:00AM CST
RTI Surgical Inc.(TM) (RTI) (Nasdaq: RTIX), a leading global surgical implant company, announced that The Journal of Spinal Disorders & Techniques published a study online highlighting nanOss(R) clinical data results. NanOss is an advanced bone graft substitute that is composed of nano-structured hydroxyapatite granules and an open structured engineered collagen carrier.
RTIX: 5.20 (unch)
RTI Surgical's (RTIX) CEO Brian Hutchison on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 11:52AM CDT
RTIX: 5.20 (unch)
RTI Surgical beats Street 3Q forecasts
Automated Insights - Thu Oct 30, 8:21AM CDT
ALACHUA, Fla. (AP) _ RTI Surgical Inc. (RTIX) on Thursday reported earnings of $2 million in its third quarter.
RTIX: 5.20 (unch)
RTI Surgical beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 7:05AM CDT
RTIX: 5.20 (unch)
RTI Surgical(TM) Announces 2014 Third Quarter Results
Business Wire - Thu Oct 30, 7:02AM CDT
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, reported operating results for the third quarter of 2014 as follows:
RTIX: 5.20 (unch)
RTI Surgical (RTIX) Jumps: Stock Moves 12.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 8:46AM CDT
RTI Surgical (RTIX) was a big mover last session, with shares rising nearly 13% on the day.
ATEC: 1.27 (-0.06), RTIX: 5.20 (unch), EW: 130.75 (+1.17), ANGO: 19.19 (+0.33)
RTI Surgical reports October 30
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 9:22AM CDT
RTIX: 5.20 (unch)
RTI Surgical(TM) Schedules 2014 Third Quarter Earnings Conference Call for October 30, 2014
Business Wire - Thu Oct 23, 8:00AM CDT
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, announced today that it plans to release financial results from the third quarter 2014 on Thursday, October 30, 2014, prior to the market open.
RTIX: 5.20 (unch)
Shirley A. Weis Joins RTI Surgical Board of Directors
Business Wire - Wed Oct 22, 3:00PM CDT
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, announced today that Shirley A. Weis, president of Weis Associates, LLC and emerita Vice President & Chief Administrative Officer of Mayo Clinic, has joined the company's board of directors. She will be eligible for re-election at the 2015 annual meeting.
RTIX: 5.20 (unch)
U.S. Market for Soft Tissue Reinforcement and Regeneration 2015
M2 - Wed Oct 15, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/69mg7x/u_s_market_for) has announced the addition of the "U.S. Market for Soft Tissue Reinforcement and Regeneration 2015" report to their offering. The U.S. market for soft tissue reinforcement and regeneration includes medical graft devices that are designed to reinforce and regenerate soft tissues. Soft tissues are defined as aggregations of similarly specialized cells which collectively function to connect, support or surround other structures and organs of the body. These tissues include tendons, ligaments, fascia, skin, fibrous tissues, fat, synovial membranes, muscles, nerves and blood vessels. Collagen, the most abundant protein in mammals, is one of the characteristic elements inside the extracellular matrix of soft tissue and, as such, plays a critical role in soft tissue repair. Since soft tissue essentially makes up the majority of a person and there are countless medical conditions associated with soft tissue problems, a select group of large markets related to soft tissue repair will be covered in this report, including breast reconstruction, hernia repair, dural repair, vaginal slings, skin repair, sports medicine and tendon reinforcement, and dental soft tissue regeneration. There are three primary classes of soft tissue repair devices; - Allografts - Xenografts - Alloplasts Key Topics Covered: 1. Executive Summary 2. Research Methodology 3. U.S. Soft Tissue Reinforcement And Regeneration Market 4. Procedures 5. Breast Reconstruction Market 6. Hernia Repair Market 7. Dural Repair Market 8. Vaginal Sling Market 9. Skin Repair Market 10. Sports Medicine And Tendon Reinforcement Market 11. Dental Soft Tissue Regeneration Market 12. Abbreviations Companies Mentioned - Aesculap/B. Braun - American Medical Systems - Arthrex - Atrium Medical - BioHorizons - Boston Scientific - C. R. Bard - Citagenix - Coloplast - Cook Medical - Covidien - Dentsply - Depuy Synthes - Ethicon - Geistlich - Gore Medical - Integra LifeSciences - LifeCell - Medline - Medtronic - MiMedx - Organogenesis - Osiris - RTI Biologics - Smith & Nephew - Stryker - Synovis/Baxter - Systagenix - Wright Medical - Zimmer For more information visit http://www.researchandmarkets.com/research/69...market_for
BSX: 13.13 (+0.07), SNN: 38.18 (+0.14), RTIX: 5.20 (unch), MDT: 74.08 (+0.31)